John Charles Canning Buys 4,375 Shares of Femasys (NASDAQ:FEMY) Stock

Femasys Inc. (NASDAQ:FEMY) COO John Charles Canning bought 4,375 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were purchased at an average price of $3.20 per share, for a total transaction of $14,000.00. Following the transaction, the chief operating officer directly owned 4,375 shares of the company’s stock, valued at approximately $14,000. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

Femasys Price Performance

Shares of NASDAQ FEMY opened at $2.35 on Thursday. The stock has a market cap of $7.10 million, a PE ratio of -0.44 and a beta of -2.08. The company has a quick ratio of 1.98, a current ratio of 3.91 and a debt-to-equity ratio of 0.53. Femasys Inc. has a 52-week low of $2.19 and a 52-week high of $22.20. The business has a 50-day moving average price of $3.77 and a 200 day moving average price of $7.42.

Analyst Ratings Changes

Several research firms have recently weighed in on FEMY. Weiss Ratings raised Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. Wall Street Zen raised shares of Femasys to a “hold” rating in a report on Saturday, June 13th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $80.00.

Key Headlines Impacting Femasys

Here are the key news stories impacting Femasys this week:

• Positive Sentiment: Femasys secured new U.S. and international patents covering FemBloc’s blended polymer, complementing existing delivery-system patents. The broader protection across the U.S., Europe, Japan, South Korea, Brazil, India and other markets could strengthen FemBloc’s competitive position and support future licensing or commercialization partnerships. FemBloc is already approved in Europe, the U.K. and New Zealand, although it remains investigational in the United States. Femasys Strengthens and Extends Global Patent Protection for FemBloc
• Positive Sentiment: Multiple company insiders purchased shares at $3.20, including the CEO, CFO, COO, CTO and Chief Medical Affairs executive. The purchases, totaling approximately $134,000, may be viewed as a vote of confidence by management, though the transactions are relatively small compared with the company’s potential capital needs. Femasys Insider Buying
• Neutral Sentiment: Femasys recently announced a $30 million private placement. The financing should provide substantial funds for operations and the ongoing FINALE pivotal trial, but investors need to assess the security terms and potential dilution before determining its net impact on existing shareholders. Femasys Completes $30 Million Private Placement Financing
• Negative Sentiment: FemBloc still requires successful completion of its U.S. pivotal trial and FDA approval. The company continues to face significant clinical, regulatory and commercialization risks, while Femasys remains unprofitable. Shares are trading well below their 50-day and 200-day moving averages, reflecting persistent investor caution.

Hedge Funds Weigh In On Femasys

A number of hedge funds and other institutional investors have recently made changes to their positions in FEMY. Jane Street Group LLC purchased a new stake in Femasys during the 4th quarter valued at approximately $62,000. Banco BTG Pactual S.A. acquired a new stake in Femasys during the 4th quarter worth approximately $88,000. Geode Capital Management LLC grew its stake in shares of Femasys by 50.8% in the 4th quarter. Geode Capital Management LLC now owns 389,280 shares of the company’s stock valued at $224,000 after purchasing an additional 131,052 shares during the last quarter. Cetera Investment Advisers purchased a new position in shares of Femasys in the 4th quarter valued at approximately $36,000. Finally, State Street Corp increased its holdings in shares of Femasys by 43.5% in the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after purchasing an additional 24,500 shares during the period. Hedge funds and other institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.